Santen Pharmaceutical Co., Ltd.
4536
Rang in aandelen
#4360
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
Aandeelprijs
$11.24
Marktkapitalisatie
$3.61B
Verandering (1 dag)
-0.17%
Verandering (1 jaar)
11.22%
Land
JP
Handel Santen Pharmaceutical Co., Ltd. (4536)
Categorie
Healthcare
Aandelsplitsingen voor Santen Pharmaceutical Co., Ltd. (4536)
Het aandeel Santen Pharmaceutical Co., Ltd. (symbool: 4536) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel 4536 dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen 4536.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel 4536 dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen 4536.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | |||
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 4 | x15 |
US
|
|
| 7 | x432 |
US
|
|
| 0 | - |
US
|
|
| 7 | x226 |
US
|
|
| 2 | x10000 |
CH
|
